Arbor Biotechnologies Establish Strategic Partnership With 4DMT

Arbor Biotechnologies Establish Strategic Partnership With 4DMT

Client News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
We leverage technical knowledge, business acumen and legal experience to structure, prepare and negotiate innovative and effective technology-related agreements.

On January 3, 2024, Arbor Biotechnologies, a next-generation gene editing company developing potentially curative therapeutics for patients with serious diseases announced a strategic partnership with 4D Molecular Therapeutics, a leading clinical-stage genetic medicines company that aims to unlock the full potential of genetic medicines to treat large market diseases. As part of the partnership, Arbor and 4DMT will focus on advancing new AAV-based gene-editing therapies for central nervous system diseases with high unmet medical needs in both rare and common disease populations.

The WilmerHale team advising Arbor consisted of Sarah Hogan and Elese Hanson. 

 

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel